Conference item
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
- Abstract:
-
The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Volume:
- 26
- Issue:
- 22
- Pages:
- 2788-2795
- Host title:
- Vaccine
- Publication date:
- 2008-05-01
- Event location:
- Netherlands
- DOI:
- EISSN:
-
1873-2518
- ISSN:
-
0264-410X
- Source identifiers:
-
67014
Item Description
- Keywords:
- Pubs id:
-
pubs:67014
- UUID:
-
uuid:b7a4101b-d59c-4f2b-8956-bbcb57d3a8b5
- Local pid:
- pubs:67014
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2008
If you are the owner of this record, you can report an update to it here: Report update to this record